Astressin-B: A Long-Acting CRF Receptor Antagonist Studied in Stress-Linked Hair Cycling

Research summary. Astressin-B is a synthetic peptide antagonist of the corticotropin-releasing factor (CRF) receptor family, with non-selective activity at both CRF₁ and CRF₂ receptor subtypes. It was developed as a research tool for probing peripheral CRF signalling, and it became widely cited in the alopecia research community after a 2011 mouse study reported striking pigmentation and hair regrowth in a chronic-stress transgenic model.

Molecular profile

• Class: Long-acting non-selective CRF₁/CRF₂ peptide antagonist
• Origin: Synthetic analogue developed in the laboratory of Jean Rivier at the Salk Institute
• Primary action: Competitive antagonism at corticotropin-releasing factor receptors

Astressin-B is a structurally constrained CRF analogue. Substitutions and lactam-bridge stabilisations introduced relative to the parent CRF sequence improve its receptor-binding affinity, lengthen its duration of action, and confer non-selective antagonism across the CRF₁ and CRF₂ subtypes — which distinguishes it from selective antagonists such as antalarmin (CRF₁) or astressin₂-B (CRF₂).

Mechanism of action

CRF is the apex hypothalamic neuropeptide that initiates the hypothalamic–pituitary–adrenal (HPA) stress axis, but CRF and its receptors are also expressed in peripheral tissues, including skin, gastrointestinal tract, and reproductive organs. Astressin-B binds the extracellular domain of CRF₁ and CRF₂ receptors and prevents agonist-induced activation, thereby silencing both central and peripheral CRF signalling for an extended duration following a single administration.

In the skin specifically, peripheral CRF signalling has been implicated in modulating hair follicle cycling, melanocyte activity, and local immune responses. Excess peripheral CRF tone has been hypothesised to promote follicle entry into telogen (resting phase) and suppress pigmentation.

Preclinical research highlights

The Wang et al. 2011 alopecia study. The most cited investigation of astressin-B was conducted in CRF-overexpressing transgenic mice — a model in which chronic CRF excess produces a Cushing-like phenotype that includes adult-onset alopecia. A short course of peripheral astressin-B treatment in adult alopecic mice produced rapid skin pigmentation followed by visible hair regrowth that persisted for months after treatment cessation. Comparator arms using the selective CRF₂ antagonist astressin₂-B and the selective CRF₁ antagonist NBI-27914 produced markedly weaker effects, suggesting that combined antagonism of both receptor subtypes was needed for the full response. Topical and systemic minoxidil, included as a positive control, produced only partial regrowth in this model [1].

Prevention of alopecia onset. In younger CRF-overexpressing mice that had not yet developed alopecia, astressin-B administration both induced pigmentation and reduced subsequent hair loss compared with saline-treated littermates — supporting a role in interrupting progression rather than only reversing established disease in the model.

Histological findings. Skin biopsies from treated mice showed restoration of follicle morphology and a transition from a telogen-like state toward anagen (active growth phase), consistent with a real biological reset of follicle cycling rather than a cosmetic surface effect.

Selectivity for the hair phenotype. Notably, astressin-B did not normalise plasma corticosterone levels or reverse other Cushing-like features (elevated adrenal weight, visceral adiposity) in the transgenic mice. This argued against a global endocrine correction and pointed toward a more targeted mechanism operating at the level of peripheral CRF–follicle signalling.

Other CRF-related models. Astressin-B has been used as a research tool in other settings where peripheral CRF signalling is implicated, including gastrointestinal motility models and stress-induced visceral hypersensitivity studies, where the peptide has been reported to attenuate CRF-driven responses.

Limitations of the available evidence

The hair regrowth findings derive from a transgenic mouse model with a specific genetically induced phenotype. Translation to other forms of alopecia in humans (androgenetic, alopecia areata, telogen effluvium of varying aetiology) cannot be assumed. The peptide is not orally bioavailable, and its efficacy in chronic systemic dosing has not been established outside the transgenic model.

Current research status

Astressin-B remains a research-grade peptide tool and has not been advanced into formal human clinical development for alopecia or any other indication. It continues to serve as a reference compound for studies probing CRF receptor pharmacology, peripheral CRF signalling in skin and gut, and the role of stress neuropeptides in hair follicle biology.

The translational interest in CRF-receptor blockade for stress-linked alopecia remains active in the academic literature, but so far without a regulated therapeutic emerging from the pathway.

Key takeaways for researchers

• Astressin-B is a long-acting, non-selective CRF₁/CRF₂ peptide antagonist used primarily as a research tool.
• Its prominence in the peptide research community traces to a 2011 transgenic mouse study showing pigmentation and hair regrowth after short-course peripheral administration.
• Selective CRF₁ or CRF₂ antagonists did not reproduce the full hair-cycle effect, supporting a need for combined receptor blockade in this model.
• All efficacy data are preclinical and model-specific. Astressin-B is not an approved therapeutic.

References

1. Wang L, Million M, Rivier J, et al. CRF receptor antagonist astressin-B reverses and prevents alopecia in CRF over-expressing mice. PLoS ONE. 2011;6(2):e16377.
2. Gulyas J, Rivier C, Perrin M, et al. Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Proceedings of the National Academy of Sciences USA. 1995;92(23):10575–10579.

---

This article is provided for educational and research purposes only. Astressin-B is a research peptide. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.